Exelixis Inc. (EXEL)
Here's Why Exelixis (EXEL) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exelixis, Inc. (EXEL) Q1 2026 Earnings Call Transcript
Exelixis, Inc. (EXEL) Q1 2026 Earnings Call Transcript
Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Exelixis (EXEL) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Exelixis (EXEL) Tops Q1 Earnings Estimates
Exelixis (EXEL) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.62 per share a year ago.
Here's Why Exelixis (EXEL) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Exelixis (EXEL) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Exelixis: The Double Backbone Potential Of CABOMETYX And Zanzalintinib
Exelixis is positioned to evolve into a multi-franchise oncology company, anchored by CABOMETYX and the emerging zanzalintinib. CABOMETYX remains a durable cash generator, while zanzalintinib is expected to drive significant growth, with peak sales estimates of $5B by 2033. 2026 guidance projects $2.52B–$2.62B in revenue, excluding potential zanzalintinib contributions, as the company maintains robust R&D and share repurchases.
Exelixis: Stable Demand And High Margins With Undervalued Shares
Exelixis is undervalued, trading at a discount to sector and historical multiples despite robust double-digit growth and operational excellence. EXEL maintains high margins, generates strong FCF, and funds growth without increasing debt while aggressively repurchasing shares. Cabometyx drives most revenue, but management is investing heavily in R&D to diversify the portfolio and sustain future growth.
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
